Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Feng Gao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1425-1623; OpenAlex author ID A5008654358. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 9

  1. Alternative Splicing of Secretin Receptor (SCTR) and Its Low Expression Drive the Occurrence of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002569↗
  2. Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer. Co-author DOI 10.1126/sciadv.aei1190↗
  3. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology. Co-author DOI 10.1007/s00262-023-03463-x↗
  4. Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansio… Co-author DOI 10.1158/1078-0432.ccr-23-2993↗
  5. Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. Co-author DOI 10.1158/1078-0432.ccr-22-0308↗
  6. A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.15653↗
  7. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. Co-author DOI 10.1371/journal.pone.0077243↗
  8. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. Co-author DOI 10.6092/1590-8577/913↗
  9. Influence of obesity and other risk factors on survival outcomes in patients undergoing pancreaticoduodenectomy for pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318215a9b1↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. William G. Hawkins · 6 shared papers, 2011–2026 · strength 0.64
  2. Kian‐Huat Lim · 5 shared papers, 2017–2026 · strength 0.63
  3. Andrea Wang‐Gillam · 7 shared papers, 2011–2026 · strength 0.58
  4. Yanqi Ke · 1 shared paper, 2026 · strength 0.43
  5. Qicai Liu · 1 shared paper, 2026 · strength 0.43
  6. David G DeNardo · 4 shared papers, 2013–2023 · strength 0.42
  7. William E. Gillanders · 2 shared papers, 2023–2026 · strength 0.33
  8. Albert Craig Lockhart · 4 shared papers, 2012–2023 · strength 0.30
  9. Benjamin R. Tan · 3 shared papers, 2012–2023 · strength 0.27
  10. Robert R. McWilliams · 3 shared papers, 2012–2023 · strength 0.27
  11. Brett H. Herzog · 2 shared papers, 2022–2023 · strength 0.24
  12. Jad I. Belle · 2 shared papers, 2022–2023 · strength 0.24
  13. Katrina Sophia Pedersen · 2 shared papers, 2022–2023 · strength 0.24
  14. Carl DeSelm · 1 shared paper, 2026 · strength 0.19
  15. Dominic E. Sanford · 1 shared paper, 2026 · strength 0.19
  16. Felicia Zhang Perkins · 1 shared paper, 2026 · strength 0.19
  17. Roheena Z. Panni · 1 shared paper, 2026 · strength 0.19
  18. Elizabeth M. Jaffee · 1 shared paper, 2026 · strength 0.19
  19. Daniel A. Laheru · 1 shared paper, 2026 · strength 0.19
  20. John M. Baer · 1 shared paper, 2023 · strength 0.14
  21. Daoxiang Zhang · 1 shared paper, 2023 · strength 0.14
  22. Usman Younis Panni · 1 shared paper, 2023 · strength 0.14
  23. C. Alston James · 1 shared paper, 2023 · strength 0.14
  24. David C. Linehan · 3 shared papers, 2011–2013 · strength 0.09
  25. Vladimir M. Kushnir · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.